New ultra-low-dose CT scan aims to protect kids with rare blood vessel disorder
NCT ID NCT04874558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new ultra-low-dose chest CT technique in 3 children (ages 1-17) with hereditary hemorrhagic telangiectasia (HHT) to see if it could detect abnormal blood vessels in the lungs (PAVMs) using much less radiation than standard CT. The goal was to find the lowest possible radiation dose that still gives clear, usable images. This approach could make screening safer for children who need repeated scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill to stop the bleeding? new hope for HHT nosebleeds
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Blood thinners in HHT: a risky balancing act under the microscope
- Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
- New antibody aims to tame rare bleeding disorder
- New drug aims to stop nosebleeds in rare blood vessel disorder